PharmaDrug Inc (CSE:BUZZ) (OTCPINK:LMLLF) CEO Daniel Cohen tells Proactive the group has reached an agreement with Southwest Research Institute (SwRI) to initiate clinical and non-clinical manufacturing of Cepharanthine for the company's rare cancer and infectious diseases programs. Cohen says PharmaDrug is focused on advancing the clinical development of an improved oral formulation of Cepharanthine to treat esophageal cancer, based on compelling preclinical data and a streamlined path to approval, thanks to a an FDA Orphan Drug Designation.
PharmaDrug signs deal to begin manufacturing potential esophageal cancer treatment
